Spots Global Cancer Trial Database for pi3k inhibitor
Every month we try and update this database with for pi3k inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | NCT03151057 | B Cells-Tumors B Cell Chronic ... Follicular Lymp... Mantle Cell Lym... Large B-Cell Di... | Idelalisib 100 ... Placebo Oral Ta... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas | NCT01732926 | Indolent Non-Ho... | Idelalisib Rituximab Bendamustine Placebo | 18 Years - | Gilead Sciences | |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma | NCT04038359 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | NCT02049541 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | NCT03151057 | B Cells-Tumors B Cell Chronic ... Follicular Lymp... Mantle Cell Lym... Large B-Cell Di... | Idelalisib 100 ... Placebo Oral Ta... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | NCT04342117 | Lymphoma, Small... Lymphoma Lymphoma, Non-H... Chronic Lymphoc... Follicular Lymp... | duvelisib PI3K inhibitor | 18 Years - | SecuraBio | |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma | NCT02049541 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Splenic Margina... Waldenström Mac... | PI3K inhibitor ... rituximab Pharmacodynamic... Correlative stu... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | NCT04193293 | Head and Neck S... | Duvelisib Pembrolizumab | 18 Years - | SecuraBio | |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | NCT01816594 | HER2-positive N... | BKM120 Trastuzumab Paclitaxel BKM120 Placebo | 18 Years - | Novartis | |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer | NCT01816594 | HER2-positive N... | BKM120 Trastuzumab Paclitaxel BKM120 Placebo | 18 Years - | Novartis | |
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer | NCT01629615 | Breast Cancer | BKM120 | 18 Years - | SOLTI Breast Cancer Research Group | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | NCT02144038 | Relapsed and Re... | LGH447 BYL719 | 18 Years - | Novartis | |
| A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | NCT01882803 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | NCT01882803 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies | NCT01682473 | Neoplasms | ZSTK474 | 20 Years - | Zenyaku Kogyo Co., Ltd. | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor | NCT05429398 | Advanced Solid ... | Linperlisib Tab... | 18 Years - 75 Years | Shanghai YingLi Pharmaceutical Co. Ltd. | |
| Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | NCT01719380 | Colorectal Canc... | LGX818 Cetuximab BYL719 | 18 Years - | Pfizer | |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | NCT01911325 | Squamous Non-sm... | Buparlisib Buparlisib matc... Docetaxel | 18 Years - | Novartis | |
| Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma | NCT02144038 | Relapsed and Re... | LGH447 BYL719 | 18 Years - | Novartis | |
| A Multicenter Phase II Pilot Open Label | NCT01830504 | Thyroid Cancers | BKM120 | 18 Years - | Hospices Civils de Lyon | |
| MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) | NCT04495621 | Metastatic Colo... | MEN1611 Cetuximab | 18 Years - | Menarini Group | |
| Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00996892 | Solid Tumors | Cobimetinib Pictilisib | 18 Years - | Genentech, Inc. | |
| A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects With Indolent Non-Hodgkin Lymphoma | NCT04038359 | Indolent Non-Ho... | Duvelisib | 18 Years - | SecuraBio | |
| A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | NCT00620594 | Breast Cancer Advanced Solid ... Cowden Syndrome | BEZ235 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
